Pfenex, Inc. and Cedarlane have entered into a non-exclusive distribution agreement under which Cedarlane will market and distribute Pfenex reagent proteins to researchers in the U.S. and Canada. The products will include vaccine carrier proteins such as CRM197 and Cholera Toxin B, and cell culture-related growth factors including G-CSF and Interferon beta 1-b. New products developed by Pfenex will be added upon launch. Patrick K. Lucy, vice president, business development at Pfenex, remarked...